Seattle Genetics Profile

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>SGE</div>


0 / 100

Odds of Distress

Equity ratings for Seattle Genetics are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 24, 2019 and ending today February 22, 2020. Click here to learn more.

Seattle Genetics Profile

Next fiscal quarter end is expected on March 31, 2020. Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington. Seattle Genetics operates under Pharmaceuticals And Biosciences classification in USA and is traded on BATS Exchange. more on Seattle Genetics
Legal NameSeattle Genetics
ChairmanClay SiegallView All
Thematic Classification
Currently Active Investing Idea
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Seattle Genetics
Piotroski F Score
Academic score to determine the current strength of Seattle Genetics financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Few selected profitability drivers of Seattle Genetics representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Net Income Per Employee
Operating Margin
Gross Margin
Profit Margin
Seattle Genetics (SGEN) is traded on BATS Exchange in USA and employs 1,302 people. The company currently falls under 'Large-Cap' category with current market capitalization of 20.34 B. Seattle Genetics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 171.39 M outstanding shares of which 4.95 M shares are at this time shorted by private and institutional investors with about 4.13 trading days to cover. SEATTLE GENETICS currently holds about 811.05 M in cash with (163.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72.
Check Seattle Genetics Probability Of Bankruptcy

Ownership Allocation (%)

Seattle Genetics Target Price Odds Analysis

Odds Below 119.89HorizonTargetOdds Above 119.89
90.96%30 days 119.89 8.90%
Based on normal probability distribution, the odds of Seattle Genetics to move above current price in 30 days from now is about 8.9 (This Seattle Genetics probability density function shows the probability of Seattle Genetics Stock to fall within a particular range of prices over 30 days) .

Seattle Genetics Top Holders

Seattle Genetics Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Baker Bros Advisors LpCommon Shares50.1 M5.7 B
Capital International InvestorsCommon Shares18.3 M2.1 B
View Seattle Genetics Diagnostics

Seattle Genetics Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Seattle Genetics Against Markets

Did you try this?

Run Premium Stories Now


Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Seattle Genetics Upcoming and Recent Events

Seattle Genetics Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportApril 23, 2020
Next Earnings ReportJuly 21, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 4, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

Seattle Genetics Corporate Directors

Pinkston Peggy Senior Director - Corporate Communications
David Gryska Independent Director
Daniel Welch Independent Director
Additionally take a look at World Market Map. Please also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.
Company logos by clearbit